Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 679 across all filing types
Latest filing 2025-06-12 Investor Presentation
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at EHA 2025
Investor Presentation Classification · 95% confidence The document is a press release announcing updated clinical data for a drug candidate (BI-1808) being presented at a medical conference (EHA 2025). It details preliminary efficacy, safety, and mechanism of action. It is not a formal regulatory filing like a 10-K or IR, nor is it a transcript (CT) or a formal dividend notice (DIV). Since it is an announcement of clinical trial results and scientific data presentation, it most closely aligns with an Investor Presentation (IP) or a general announcement. Given the context of biotech updates, which often serve as investor communications detailing scientific progress, 'Investor Presentation' (IP) is a strong fit, although it is technically a press release. However, looking at the definitions, it is a communication detailing scientific progress and results intended for investors and the public. It is not a formal 'Earnings Release' (ER) as it focuses on clinical trials, not quarterly financials. It is also not a 'Report Publication Announcement' (RPA) because it contains the substantive data itself, not just a notice that a report is available. Therefore, 'Investor Presentation' (IP) best captures the nature of this detailed scientific/clinical update aimed at the investment community.
2025-06-12 English
XOMA Royalty förvärvar mezagitamab royalty- och milstolpsrättigheter av BioInvent International för upp till 30 miljoner USD
Capital/Financing Update Classification · 98% confidence The document is a press release dated May 27, 2025, announcing a specific transaction: XOMA Royalty acquiring royalty and milestone rights for mezagitamab from BioInvent International for up to $30 million. This transaction involves financing/capital infusion for BioInvent and the acquisition of future economic rights by XOMA Royalty. This fits best under 'Capital/Financing Update' (CAP) as it details a significant financial transaction involving the transfer of future revenue streams (royalties/milestones) for immediate capital. It is not a full financial report (10-K or IR), an earnings release (ER), or a general regulatory filing (RNS), but a specific announcement about a financing/asset deal.
2025-05-27 Swedish
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD 30 Million
M&A Activity Classification · 99% confidence The document is a press release dated May 27, 2025, announcing a specific corporate transaction: XOMA Royalty purchasing royalty and milestone rights from BioInvent International for up to USD 30 Million. This type of announcement, detailing a significant financial agreement, asset acquisition, or financing activity, aligns best with the Capital/Financing Update (CAP) category. It is not a full annual report (10-K), an earnings release (ER), or a management discussion (MDA). Since it details a transaction that provides non-dilutive capital to BioInvent and builds XOMA's portfolio, CAP is the most appropriate classification. The document ends with an attachment link, but the content itself is the announcement, not just a notice of publication, making CAP more specific than RPA or RNS.
2025-05-27 English
BioInvent presenterar ytterligare fas 2a-data för BI-1808 monoterapi i CTCL på EHA 2025
Regulatory Filings Classification · 95% confidence The document is a press release dated May 14, 2025, announcing that BioInvent will present further Phase 2a data for its drug candidate BI-1808 at the European Hematology Association (EHA) 2025 congress in June. It details preliminary clinical activity (CR, PR, SD) and safety findings. The text explicitly mentions that the poster will be published on the company website after the presentation date and includes a link to the attached PDF press release. This structure—announcing upcoming presentation of data and providing key highlights—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific announcement about clinical trial data presentation rather than a comprehensive financial report (10-K, IR) or a formal regulatory filing like a major shareholding change, it fits best as an Earnings Release (ER) if it were reporting period results, or a general Regulatory Filing (RNS) as it is a material, non-financial announcement. Given the focus is on clinical trial updates and presentation scheduling, and it is not a standard quarterly/annual report, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback, although ER is sometimes used for clinical updates. However, since it is primarily an announcement about *presenting* data at a conference, and not the release of the full financial results themselves, RNS is safer, or potentially RPA if it were announcing the *release* of a report, but here it announces a *presentation*. Given the options, RNS covers general material announcements not covered elsewhere. I will classify it as RNS as it is a material, non-standard announcement.
2025-05-14 Swedish
BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the treatment of non-Hodgkin's lymphoma
Regulatory Filings Classification · 95% confidence The document is a press release dated May 14, 2025, announcing updated clinical trial data for a drug candidate (BI-1206) in combination therapy for non-Hodgkin's lymphoma. It details response rates (CR, PR, SD) and mentions that the data is included in an abstract for the EHA 2025 conference. Crucially, the document ends with links to attachments and a statement that the information is being made public pursuant to the EU Market Abuse Regulation. This structure—a brief announcement summarizing key results and pointing to the full details elsewhere—is characteristic of a general regulatory announcement or press release, rather than a comprehensive financial report (like 10-K or IR) or a dedicated earnings release (ER). Since it is a formal announcement of material information required to be made public under market regulations, and it doesn't fit the specific categories like DIV, DIRS, or MANG, the most appropriate general regulatory category is RNS (Regulatory Filings), which serves as a fallback for such announcements.
2025-05-14 English
Uppdatering från BioInvents fas 2a-trippelkombinationsstudie med BI-1206, rituximab och Calquence för behandling av non-Hodgkins lymfom
Earnings Release Classification · 95% confidence The document is a press release dated May 14, 2025, announcing updated preliminary clinical results from a Phase 2a trial involving the drug candidate BI-1206 for Non-Hodgkin's Lymphoma. It details response rates (CR, PR, SD) and mentions that an abstract with earlier data was published by the European Hematology Association (EHA) 2025 conference. The text is a direct announcement of clinical trial progress and financial/operational news, typical of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on providing key financial/clinical highlights immediately (response rates, CEO quote) rather than being a comprehensive quarterly report (IR) or a transcript (CT), it fits best as an Earnings Release (ER) announcing key operational results, even though the results are clinical rather than purely financial. The final paragraph confirms it is information the company is obliged to disclose under EU market abuse regulation, which often accompanies ERs or RNS filings. Given the focus on immediate results and highlights, ER is the most appropriate specific code over the general RNS. Q2 2025
2025-05-14 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.